Compare AbCellera Biologics Inc (ABCL) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Harmony Gold Mining Co. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Harmony Gold Mining Co. trades at $14.42 (market cap $9.60B). The key difference: Harmony Gold Mining Co. is far larger — about 4.1× AbCellera Biologics Inc's market cap, and Harmony Gold Mining Co. pays a 2.65% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HMY | |
|---|---|---|
Market Cap | $2.35B | $9.60B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $26.04 |
52-Week Low | $2.78 | $12.61 |
Enterprise Value | $1.99B | $9.93B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Harmony Gold Mining (HMY) trades at $15.385, down 4.38% amid broader gold sector weakness. The stock shows strong fundamentals with 2024 revenue of $61.38B and net income of $8.59B, representing a 13.99% margin. Technical indicators signal bearish momentum with RSI at oversold levels. Recent earnings beat expectations in Q2 2025 but missed in Q4 2025, while analysts maintain a cautious stance with 70% hold ratings.
HMY presents value with attractive valuation ratios (P/E 10.42, EV/EBITDA 5.36) and robust profitability (ROE 32.32%). However, Fed rate hike concerns and gold price volatility pose near-term headwinds. The company's transition to gold-copper hybrid operations by 2028 offers long-term growth potential, though execution risks and commodity price exposure remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
